XOMA Royalty Corp

Analysis for Ticker: XOMA

Xoma Royalty Corp operates as a financial middleman that buys rights to future medicine payments from drug candidates like Vabysmo and Ojemda, letting large pharmaceutical companies pay for the expensive science while it waits to collect a check. But the check is already spent. The company sits on a staggering 1,2$ billion accumulated deficit. The core mechanism is not a business, but a financial drain where special instruments called cumulative perpetual preferred shares act like private cups that catch all the cash before anyone else can have a drink. Think of it like a bank account that owes a never-ending 8,625% and 8,375% fee every single year. Even if the account is empty, the bill just keeps growing until the next deposit arrives, ensuring the common owners are always mathematically last in line.